SRPT - Sarepta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
79.99
+1.44 (+1.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close78.55
Open78.21
Bid80.05 x 100
Ask81.90 x 100
Day's Range77.67 - 80.87
52 Week Range28.82 - 84.37
Volume1,297,319
Avg. Volume1,392,344
Market Cap5.198B
Beta1.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • A Look at Sarepta Therapeutics’ Cash Flows
    Market Realistyesterday

    A Look at Sarepta Therapeutics’ Cash Flows

    Sarepta Therapeutics (SRPT) posted $231.9 million in operating activities in fiscal 2017 compared with $245.8 million in fiscal 2016. This decrease of $13.8 million in fiscal 2017 was primarily due to a decrease of $91.6 million in a net loss. This trend was driven by higher product revenues of Exondys and a decrease in research and development expenses due to capitalization of inventory. 

  • Exploring the Financial Performance of Sarepta Therapeutics
    Market Realist2 days ago

    Exploring the Financial Performance of Sarepta Therapeutics

    How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) generated revenues of $154.5 million in fiscal 2017 compared with $5.4 million in fiscal 2016. The substantial increase in revenues shows the increasing demand for the product.

  • Exploring the Product Candidates of Sarepta Therapeutics
    Market Realist2 days ago

    Exploring the Product Candidates of Sarepta Therapeutics

    How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics’ (SRPT) Exondus was granted accelerated approval by the FDA in September 2016. Sarepta Therapeutics’ golodirsen is an exon 53 skipping drug candidate.

  • Analysts’ Ratings for Sarepta Therapeutics and Peers in April
    Market Realist2 days ago

    Analysts’ Ratings for Sarepta Therapeutics and Peers in April

    How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.

  • Investopedia4 days ago

    Why Big Biotech Stocks May Get An Earnings Boost

    Big Bounce: Big biotech stocks may surge on better-than-expected quarterly results

  • See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. The net inflows of $171 million over the last one-month into ETFs that hold SRPT are among the lowest of the last year and appear to be slowing.

  • Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid
    American City Business Journals10 days ago

    Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid

    All three companies are developing drugs made up of a shortened version of the dystrophin gene, which normally protects muscle cells but is absent in boys with Duchenne.

  • See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. Over the last month, ETFs holding SRPT are favorable, with net inflows of $3.08 billion.

  • What Drove Sarepta Therapeutics Stock in March 2018?
    Market Realist13 days ago

    What Drove Sarepta Therapeutics Stock in March 2018?

    Sarepta Therapeutics (SRPT) stock has risen 19.3%, from $62.11 on March 1, 2018, to $74.09 on March 29, 2018. Its less-than-expected loss in 4Q17, mainly due to solid sales of EXONDYS 51 and nearly double the projected sales for EXONDYS 51 in fiscal 2018 compared to fiscal 2017, catapulted the stock from $62.11 on March 1, 2018, to $71.45 on March 5, 2018. On April 4, 2018, Sarepta Therapeutics was trading 263% above its 52-week low of $28.14 and 12.3% below its 52-week high of $84.37.

  • TheStreet.com16 days ago

    Sarepta Hit With Call to Drop Duchenne Drug Costs

    The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

  • How BioMarin Pharmaceutical Performed in 4Q17 and 2017
    Market Realist19 days ago

    How BioMarin Pharmaceutical Performed in 4Q17 and 2017

    A Post-4Q17 Update on BioMarin PharmaceuticalsBioMarin Pharmaceutical’s revenue trends

  • Why Spark Therapeutics Stock Rose in the Week Ended March 29
    Market Realist19 days ago

    Why Spark Therapeutics Stock Rose in the Week Ended March 29

    A Look at Pharma's Gainers in the Week Ended March 29

  • Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
    Market Realist19 days ago

    Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

    On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.

  • Investopedia21 days ago

    3 Hot Biotech Stocks Facing Sharp Declines

    A review of charts and trading patterns suggest these stocks could fall by 10% in the coming weeks. 

  • Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report?
    Zacks21 days ago

    Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report?

    Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Investors sue Solid Biosciences, say they were duped about Duchenne drug’s safety
    American City Business Journals25 days ago

    Investors sue Solid Biosciences, say they were duped about Duchenne drug’s safety

    The Cambridge biotech raised $125 million in an IPO in January, but saw its stock price plummet earlier this month after disclosing that the FDA had halted a trial of the drug.

  • Benzingalast month

    Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics

    Multiple small- and mid-cap biotech stocks have benefited from a strong run, prompting Morgan Stanley to downgrade three companies in the group. The Analyst Morgan Stanley's Matthew Harrison downgraded ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of SRPT earnings conference call or presentation 1-Mar-18 9:30pm GMT

    Q4 2017 Sarepta Therapeutics Inc Earnings Call

  • Benzingalast month

    Netflix Looks Like It's In For More Downside, And 4 Other Stocks To Watch This Week

    In light of Monday's volatility, here are five stocks to watch this week according to VantagePoint , a platform that uses artificial intelligence and Intermarket analysis to predict price movement.  What's ...

  • MarketWatchlast month

    Solid Biosciences shares crater 63% on clinical hold for lead product

    The development, which follows a partial clinical hold on the same product last year, raises ‘multiple concerns,’ J.P. Morgan analysts said.

  • Sarepta Buoyed As Rival Craters On Muscular Dystrophy Drug Ruling
    Investor's Business Dailylast month

    Sarepta Buoyed As Rival Craters On Muscular Dystrophy Drug Ruling

    Sarepta extended its lead in Duchenne muscular dystrophy on Thursday as new rival Solid Biosciences cratered after the FDA placed its trial on a clinical hold.

  • Barrons.comlast month

    Solid Biosciences' Pain Is Sarepta's Gain

    Shares of Sarepta Therapeutics (SRPT) are higher on Thursday, after rival Solid Biosciences' (SLDB) microdystrophin gene transfer program for Duchenne muscular dystrophy (DMD), was put on clinical hold.  Solid Biosciences had to pause its IGNITE DMD clinical trial on safety concerns, after the first patient who received the gene therapy about a month ago was hospitalized due an unexpected event, including a reduced red-blood-cell count. Although the patient is recovering, Solid Biosciences reported the incident, given that it was unexpected, leading to the hold. W.C. Wainwright's  Debjit Chattopadhyay reiterated a Buy rating and $92 price target on Sarepta today, writing that given the differences in the drugs and their evolving safety profiles, Solid Biosciences's setback looks like good news for Sarepta, which investors should buy "in the event of any collateral damage stemming from the Solid Biosciences clinical hold." He argues that the news will fortify the perception that Solid Biosciences' offering is a "potentially risky alternative" to Sarepta's competing investigational drug, and it may make it harder for Solid Biosciences to enroll patients in trials, especially if Sarepta continues to report positive news.

  • Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug
    Zackslast month

    Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug

    Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.

  • See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.

    Sarepta Therapeutics Inc NASDAQ/NGS:SRPT

  • American City Business Journalslast month

    Shares of Solid Biosciences crater as FDA halts Duchenne gene therapy trial

    Less than two months after pulling off one of the biggest initial public offerings for a local biotech in recent years, Cambridge-based Solid Biosciences said that the FDA had halted a trial of its gene therapy treatment for Duchenne muscular dystrophy, sending shares of the company into a tailspin. Solid (SLDB) said Wednesday that the FDA had stopped an early-stage study of the drug after one patient was hospitalized due to reduced platelet and red blood cell count. "The team at Solid will be working with the principal investigator and FDA to fully understand the cause and nature of this event, as well as identify appropriate next steps as soon as possible," the company said in a statement.